AIM ImmunoTech Highlights Ampligen’s Potential in Pancreatic Cancer; DURIPANC Results Expected in 2027

AIM ImmunoTech presented data suggesting Ampligen may enhance RAS-targeted therapy for pancreatic cancer. Phase 3 DURIPANC results are expected in 2027. Ampligen-treated patients showed 19.7 months median survival vs. 12.5 months for controls. RASolute 302 showed daraxonrasib's median survival of 13.2 months vs. 6.7 months with chemotherapy.

Original reporting
Published Nov 5, 2026, 2:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 2:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AIM ImmunoTech Highlights Ampligen’s Potential in Pancreatic Cancer; DURIPANC Results Expected in 2027 — source image
Decision brief

The 30-second read

$AIMBearishMed
01

Why it matters

The filing provides the first public timeline for DURIPANC results, a material update for the company.

02

Market read

New trial timeline may influence AIM's valuation and peer comparisons.

03

What to watch

Potential partnership or licensing deals tied to the trial could add upside.

Relevance 8/10Novelty 8/10Timing: now

Background

AIM ImmunoTech highlighted Ampligen's role in pancreatic cancer and announced future Phase 3 readout dates.

Company-level read

Ticker impact

$AIMBearishMedium confidence
Context

AIM ImmunoTech filed an 8‑K presenting that Phase 3 DURIPANC results are expected in Q1 2027.

Expected impact

likely downward pressure as investors price in later data

Evidence & confidence

No new efficacy data released; only a future result date, which can reduce short‑term upside.

Market effects

May affect biotech peers tracking RAS‑targeted therapies.

Limited to US biotech investors.

Low; primarily relevant to niche oncology investors.

Counterpoint

The upcoming data could be a catalyst for a sharp rally if results exceed expectations.

Key entities

  • AIM ImmunoTech Inc.

    US‑listed biotech developing Ampligen for oncology.

Related articles

$AIMLow

AIM ImmunoTech completes dosing in pancreatic cancer trial

AIM ImmunoTech (AIM) completed dosing in its Phase 2 DURIPANC trial for pancreatic cancer, with results expected in 2027. The trial tests Ampligen with AstraZeneca's Imfinzi. AIM reported Q3 2026 cash of $6.9M, R&D expenses of $846K, and a net loss of $3.1M. The company secured patents for Ampligen combinations and repaid a promissory note.